Concurrent Session 6: Clinical Research and Epidemiology

Amphitheatre B

Date: Saturday 21 September 2019, 09.00-10.30
Room: Amphitheatre B

Chairs: Alain Taïeb, Kaisa Tasanen-Määttä

Program

09.00-09.10 057 (Poster 093)
Early major adverse cardiovascular events following the initiation of the anti-interleukin 12/23 antibody ustekinumab. A population-based case-time-control study
F Poizeau,1 E Nowak,1 S Kerbrat,1 C Droitcourt,1 E Sbidian,2 B Guillot,5 H Bachelez,3 H Ait- Oufella,4 E Oger1 and A Dupuy1 1EA 7449 REPERES (Pharmacoepidemiology and Health Services Research), Rennes, France, 2EA EpiDermE 7379, Paris Est University, Créteil, France, 3Inserm UMR1163, Institut Imagine, Paris, France, 4Inserm U970, Sorbonne University, Paris, France and 5CHU, Montpellier, France
09.10-09.20 058 (Poster 094)
Integration of multi-omic data identifies psoriasis endotypes correlating with clinical and immunological phenotypes
M Cameron,1 J Golden,1 B Richardson,1 G Damiani,2 M Ali,3 A Young,2 C Nichols,1 N Ward,3 T McCormick2 and K Cooper2 1Population & Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, 2Department of Dermatology, University Hospitals, Cleveland, OH and 3Department of Nutrition, Case Western Reserve University, Cleveland, OH
09.20-09.30 059 (Poster 110)
Host-microbial dialogues in atopic dermatitis and psoriasis
N Fyhrquist1, E Consortium2 1Karolinska Institute, Stockholm, Sweden2, EU-MAARS Consortium, Helsinki, Finland
09.30-09.40 060 (Poster 097)
Novel Genomic Signature Predicts Response to Ruxolitinib Cream in Psoriasis
H Liu and MD Howell Translational Sciences, Incyte Research Institute, Wilmington, DE
09.40-09.50 061 (Poster 087)
Revisiting pachyonychia congenita: a case cohort study in 815 patients
L Samuelov,1 F Smith,2 D Hansen3 and E Sprecher1 1Dermatology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel, 2Pachyonychia Congenita Project, Holladay, UT and 3University of Utah, Salt Lake City, UT
09.50-10.00 062 (Poster 278)
Generation and clinical application of gene modified autologous epidermal sheets in Netherton syndrome – lessons learned from a phase 1 trial
W Di,1 SM Lwin,2 A Petrova,1 C Bernadis,3 F Syed,1 AE Martinez,4 JA McGrath,2 AJ Thrasher,1 JE Mellerio2 and W Qasim1 1UCL GOS Institute of Child Health, London, United Kingdom, 2St John’s Institute of Dermatology, King’s College London, London, United Kingdom, 3Plastic Surgery Unit, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom and 4Dermatology Department, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
10.00-10.10 063 (Poster 245)
Successful treatment of Netherton syndrome with dupilumab
S Blunder, M Schmuth and R Gruber Innsbruck Medical University, Innsbruck, Austria
10.10-10.20 064 (Poster 088)
A phase I/II study on the anti-CD3/CD7 immunotoxin combination for the treatment of steroid-refractory acute GVHD
T Matos,1 FW Preijers,4 LF van Groningen,4 C Groth,3 S Blok,1 C Reicherts,3 J Levine,2 E Hooren,2 N Blijlevens,4 Y Oosterhout,2 W Velden4 and M Stelljes3 1AMC, Amsterdam, Netherlands, 2Xenicos, Nijmegen, Netherlands, 3Muenster University, Muenster, Germany and 4RadboudUMC, Nijmegen, Netherlands
10.20-10.30 065 (Poster 091)
IPH4102 (an anti-KIR3DL2 antibody) in refractory cutaneous T cell lymphoma
M Bagot,1,2 P Porcu,3 A Marie-Cardine,2 M Battistella,4 A Bensussan,2 C Paturel,5 C Bonnafous,5 H Sicard,5 H Azim5 and Y Kim6 1Dermatology, Hopital Saint Louis, Paris, France, 2INSERMU976, Paris, France, 3Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA, 4Pathology, Hopital Saint Louis, Paris, France, 5Innate Pharma, Marseille, France and 6Dermatology, Stanford Cancer Institute, Stanford, CA
Clinical ESDR Abstracts